NEJM Journal Watch - General Medicine

In a retrospective study, GLP-1 agonists were associated with slower progression to cirrhosis.

A 14-day monitor detected more atrial fibrillation but did not affect hospitalization rates for stroke or hemorrhage.

Both Cologuard Plus and Shield were approved in 2024.

Among patients with insulin-treated diabetes, hypoglycemia was common but usually asymptomatic.

A trio of trials provide more evidence for the safety and efficacy of SPCs to lower blood pressure.

A meta-analysis finds a potential signal favoring anticoagulation for patent foramen ovale and mixed results for left atrial enlargement.

Patients in their 30s had higher rates of secondary hypertension than did younger adults, which highlights potential gaps in screening recommendations.

Early diagnostic paracentesis within 12 to 24 hours was associated with lower in-hospital mortality, shorter hospital length of stay, and fewer acute kidney injuries.

Dr. Paul Sax reflects on the election outcome and gives us an ID (and non-ID) Link-o-Rama in HIV and ID Observations.

In a randomized trial, switching to zoledronate was associated with loss of bone density in the spine.